The combination of anti-CTLA-4 plus anti-PD-1 has demonstrated encouraging activity in preclinical murine models of orthotopic transplanted gliomas [45, 63, 64, 89, 90], however this has failed to translate to substantial clinical benefit (8). Here, PDCD1 is linked to glioma.